The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the key take home data from the ALPINE phase III study.
The abstract entitled ‘Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study’ was presented at ASH Annual Meeting, 10–13, December, 2022.
Questions:
- What are the limitations of ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma? (0:22)
- How does the mechanism of action of zanubrutinib offer potential advantages over ibrutinib? (1:07)
- Could you tell us a little about the ALPINE study and its primary findings? (1:38)
- What have we learned from the latest efficacy and safety data? (2:31)
- What is the key take home message from this study? (3:12)
Disclosures: Jennifer Brown is a consultant for Abbvie, Acerta/Astra-Zeneca, BeiGene, Eli Lilly, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, MEI Pharma, Numab Therapeutics, Pfizer and Pharmacyclic. She has received grant/research support from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio and TG Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Filmed as a highlight of ASH 2022
Access more content on Haematological Malignancies, Leukaemia and Lymphoma
